Skip to content

Evaluation of clinical efficacy of therapy with T-705 in patients with severe fever with thrombocytopenia syndrome

Evaluation of clinical efficacy of therapy with T-705 in patients with severe fever with thrombocytopenia syndrome

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900023350
Enrollment
Unknown
Registered
2019-05-23
Start date
2018-04-01
Completion date
Unknown
Last updated
2019-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe fever with thrombocytopenia syndrome

Interventions

Sponsors

People's Liberation Army 154th Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: patients who have to meet all of following items: 1. Clinical diagnosis: diagnostic criteria in accordance with the Ministry of Health issued by the "fever with thrombocytopenia syndrome prevention and control guidelines" implementation. Mainly based on epidemiological history (epidemic season in the hills, forest, mountain and other places of work, life or travel history or 2 weeks before the onset of tick bites history), fever and other clinical manifestations and peripheral platelets or white blood cells decreased; 2. Pathogen diagnosis: SFTSV virus nucleic acid detection positive; 3. platelet count between 30-80*10^9/L; 4. Aged between 18-80 years old, male and female

Exclusion criteria

Exclusion criteria: patients who meet any one of the following criteria will be excluded: 1. Time between admission and the disease onset is more than 7 days; 2. With high chlorine acidosis, renal insufficiency and anuria and other contraindications; 3. Receiving antiviral drugs, immunomodulatory treatment within 6 months; 4. Combined with other pathogen infections, such as HIV, syphilis, Rickettsia, Lyme disease spiral or bar Biscuits and other pathogens that can cause similar symptoms; 5. Patients with chronic basic diseases such as cancer, tuberculosis, nephropathy; 6. Recent use of antiplatelet agents or antiallergic drugs; 7. Pregnant or lactating women; 8. No or unwilling signed informed consent; 9. Patients who are participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Mortality rate;Viral Load;

Secondary

MeasureTime frame
Severe complication rate;days for platelet and white blood cells recovered to the normal level;Routine laboratory examination;Bleeding and vascular leakage symptoms;Immunological index;

Countries

China

Contacts

Public ContactCui Ning

People's Liberation Army 154th Hospital

cnblcc@sohu.com+86 13939761709

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 23, 2026